Power your success with combined pharmacy and medical data

Integrated data. Actionable insights. Pharmacist outreach.
All in one innovative product. 

Integrated data reveals savings opportunities 

Finding and supporting members with complex conditions helps lower costs for health plans, employers and members. HighTouchRx® applies exclusive clinical predictive modeling to your medical and pharmacy data, making it easy to quickly determine high-cost members and offer interventions. And the best part? HighTouchRx is available to all lines of business.

Pharmacy + medical data 

Identify 1,000+ medical drugs and pharmacy savings opportunities. 

Specialized outreach 

Partner with clinical pharmacists to provide high-touch outreach. 

Improved care 

Promote member safety and savings opportunities. 

$150M+

Since its launch, HighTouchRx has saved commercial and Medicare plans $150M+.

$12K

In 2024, our customers saw $12K average savings per converted drug across all rules.

3:1 ROI

Customers realize a 3:1 return on investment (ROI) one year after a member has implemented a recommended therapy change.1

50 NPS

HighTouchRx has achieved a 50 Net Promoter Score (NPS).2

Real-world savings

SAVINGS PER CASE

$194,300

ROI

1,275%

Exceeding guarantees

An employer group with 7,000 lives implemented HighTouchRx. They saw savings of $194,300, with HighTouchRx providing a 1,275% ROI, exceeding our guarantee.3

SAVINGS PER CASE

$11,500

Eliminating duplicate therapies

HighTouchRx identified a member who had been using both Mounjaro and Ozempic for two months. A pharmacist reached out to the provider, who switched the member to a single GLP-1 therapy, resulting in $11,500 in savings and reducing the likelihood of adverse side effects.3

Award-winning research & support

Cystic fibrosis oversupply

HighTouchRx received the Silver Award at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023. The solution uncovered an average savings of $30,732 per case, driven by refill delays when high-cost drugs were oversupplied.

See the research

Multiple sclerosis (MS) brand-to-generic switches

HighTouchRx was a Gold Award recipient at the AMCP Annual Meeting 2024, recognized for delivering an average savings of $73,142 per case for recommending conversions from high-cost brand-name MS drugs to lower-cost generics.

View the findings

Cost containment

HighTouchRx received a Platinum AMCP award for its significant impact in identifying and managing duplicate incretin therapies, demonstrating $7,578 in savings per case.

Check out the study

Footnotes

Savings and ROI numbers shown are best results that do not guarantee future results.
All brand names are property of their respective owners.

1No impact to rebates or member cost share
2HighTouchRx client satisfaction survey 2025
3Case studies based on 2024 actual results; past results do not guarantee future results

Login Portals
Compliance / Legal
Company
© 2025 Prime Therapeutics LLC